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Background. Abnormal regulation of angiogenesis in tumors results in the formation of vessels that are necessary for tumor
growth, but compromised in structure and function. Abnormal tumor vasculature impairs oxygen and drug delivery and results
in radiotherapy and chemotherapy resistance, respectively. Alpha particles are extraordinarily potent, short-ranged radiations
with geometry uniquely suitable for selectively killing neovasculature. Methodology and Principal Findings. Actinium-225
(225Ac)-E4G10, an alpha-emitting antibody construct reactive with the unengaged form of vascular endothelial cadherin, is
capable of potent, selective killing of tumor neovascular endothelium and late endothelial progenitors in bone-marrow and
blood. No specific normal-tissue uptake of E4G10 was seen by imaging or post-mortem biodistribution studies in mice. In
a mouse-model of prostatic carcinoma, 225Ac-E4G10 treatment resulted in inhibition of tumor growth, lower serum prostate
specific antigen level and markedly prolonged survival, which was further enhanced by subsequent administration of
paclitaxel. Immunohistochemistry revealed lower vessel density and enhanced tumor cell apoptosis in 225Ac-E4G10 treated
tumors. Additionally, the residual tumor vasculature appeared normalized as evident by enhanced pericyte coverage following
225Ac-E4G10 therapy. However, no toxicity was observed in vascularized normal organs following 225Ac-E4G10 therapy.
Conclusions. The data suggest that alpha-particle immunotherapy to neovasculature, alone or in combination with sequential
chemotherapy, is an effective approach to cancer therapy.
Citation: Jaggi JS, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, et al (2007) Selective Alpha-Particle Mediated Depletion of Tumor Vasculature
with Vascular Normalization. PLoS ONE 2(3): e267. doi:10.1371/journal.pone.0000267
INTRODUCTION
Inhibition of tumor angiogenesis is an emerging treatment strategy
for solid tumors [1]. Endothelium-targeting peptides, antibodies,
antibody fragments and nanoparticles have been used to target the
tumor vasculature in various preclinical and clinical studies
[2,3,4]. The ultimate goal of these anti-angiogenic strategies is to
inhibit endothelial cell proliferation in tumors via either targeted
delivery of toxins, cytotoxic drugs or radiation to endothelial cells,
interference with intercellular signaling pathways in endothelial
cells (e.g. anti-VEGF therapies) [5,6,7,8,9] or disruption of endo-
thelial cell interaction with the extracellular matrix (e.g. avb3
integrin inhibitors) [10]. Endothelial cells, unlike cancer cells, are
generally genetically and phenotypically stable and do not mutate
readily; therefore, development of drug-resistance is not a major
concern in therapies directed against endothelial cells [11].
Tumor growth inhibition via anti-angiogenic therapy has certain
practical limitations to its implementation [12]. A second wave of
angiogenesis initiated by the residual tumor cells can ensue when an
anti-angiogenic treatment is discontinued, leading to a late re-
surgence in tumor growth [13,14]. Therefore, a combination of anti-
angiogenic therapy and cytotoxic therapy that targets the tumor cells
directly has been suggested to prevent tumor recurrence. However,
destruction of tumor vasculature following anti-angiogenic therapy
can decrease blood flow to tumors and potentially prevent the
delivery of anti-tumor therapeutics to the tumor cells [12]. Recently,
Jain et al have shown that anti-angiogenic therapies may transiently
increase the efficiency of the tumor vasculature, and that adminis-
tration of cytotoxic therapy in that period may result in enhanced
cytotoxic drug delivery to tumor cells [15]. Therefore, optimal
scheduling of anti-angiogenic and chemotherapy may be required to
overcome the pharmacokinetic barriers and could potentially result
in long-term tumor remissions.
Vascular endothelial (VE) cadherin is a vascular endothelial cell
specific molecule that is expressed constitutively throughout the
entire vasculature and takes part in the formation of adherens
junctions between adjacent endothelial cells [16]. It is required for
the assembly of vascular structures during angiogenesis and main-
tenance of vascular integrity. The monoclonal antibody E4G10
specifically binds to an epitope exposed only on the monomeric,
unengaged form of VE cadherin; the epitope gets masked on
transdimerization to form inter-cellular junctions (Figure S1). This
allows for selective targeting of endothelial cells in nascent tumor
vasculature as well as of VE cadherin positive endothelial
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progenitor cells (EPCs) in bone marrow and peripheral circulation.
Since E4G10 does not bind established vasculature, no vascular
leak and hemorrhage is observed in normal organs of mice after
E4G10 administration [17]. The described properties make
E4G10 antibody an excellent targeting moiety for anti-angiogenic
therapy.
Alpha particles are extraordinarily potent, short-ranged radia-
tions with geometry uniquely suitable for selectively killing
neovasculature. A single alpha particle track through the nucleus
can kill a cell [18]. Therefore, we coupled E4G10 to chelated
Actinium-225 (225Ac, an atomic-sized generator of an alpha
particle-emitting isotope cascade [19,20]), to produce an agent
that could potently and selectively kill neovascular endothelium as
well as the endothelial progenitors in the bone marrow and blood.
Here we demonstrate, in a mouse model of prostatic carcinoma,
the safety and efficacy of the 225Ac-E4G10 construct as a selective
anti-angiogenic agent. Treatment with 225Ac-E4G10 suppressed
tumor growth, enhanced tumor cell apoptosis and prolonged
animal survival, without gross or histopathological toxicity in
normal tissues or their vasculature. Synchronized administration
of 225Ac-E4G10 and paclitaxel resulted in enhancement of the
anti-tumor response.
METHODS
Animals
Male BALB/c and athymic nude mice (NCr nu/nu), 4–12 weeks
of age, were obtained from Taconic, Germantown, NY. All animal
studies were conducted according to the NIH Guide for the care and
use of laboratory animals and were approved by the Institutional
Animal Care and Use committee at Memorial Sloan Kettering
Cancer Center.
Flow cytometry
Flow cytometric analysis of H5V and LNCaP cells was performed
with anti-CD31 (Pharmingen, San Diego, CA), E4G10, J591 (anti-
prostate specific membrane antigen) or isotype control antibodies
(R&D systems, Minneapolis, MN) and fluorochrome-labeled
secondary antibodies. Samples were acquired on an FC500 flow-
cytometer (Beckman Coulter, Fullerton, CA) and analyzed with
FlowJo software (Tree Star Inc., Ashland, OR).
Preparation, quality control and administration of
Radioimmunoconjugates
225Ac (Oak Ridge National Laboratory, Oak Ridge, TN) and
Indium-111 (111In; Perkin Elmer, Boston, MA) were conjugated to
E4G10 or non-specific rat IgG2a isotype antibody using a two-step
labeling method, as described [21]. Routine quality control of the
labeled antibody was performed using instant thin layer chroma-
tography to estimate the radio-purity and cell binding assay to
determine the immunoreactivity. Mice were anesthetized and then
injected intravenously (in retro-orbital venous plexus) with the
radioimmunoconjugate. The injected volume was 100ml and the
antibody dose was 0.6–0.7 mg per 50 nCi injection. Typical
radiochemical purity was 95–99%.
Gamma Camera imaging and biodistribution
For gamma-imaging, anesthetized animals were imaged (in prone
position) on X-SPECTTM scanner (Gamma Medica, Northridge,
CA), a dedicated rodent imaging device, at specified time-points
post-injection with 230mCi of 111In-E4G10. Images were acquired in
a 56656616 image matrix using photopeak energy windows of
172 keV610% and 273 keV610% and no zoom. For organ
distribution studies, mice were sacrificed at indicated time-points
post-injection with 111In-E4G10 (3mCi) and their blood and the
specified organs were harvested. The organs were washed in distilled
water, blotted dry on gauze, weighed and the activity of 111In (15–
550 keV window) was measured using a gamma-counter (COBRA
II, Packard Instrument Company, Meriden, CT). Samples of the
injectate (100ml) were used as decay correction standards. Percentage
of injected dose of 111In per gram of tissue weight (%ID/g) was
calculated for each animal and the mean %ID/g was determined at
each time-point, as described previously [22,23].
Tumor implantation in mice
LNCaP prostate tumor cell line was obtained from the American
Type Culture Collection (Rockville, MD). The LNCaP cells were
grown in RPMI 1640 medium supplemented with L-glutamine,
10% fetal bovine serum and penicillin-streptomycin in an
atmosphere of 5% CO2 and air at 37 degrees C. The cells were
harvested and 1 million or 5 million cells were injected in 200mL
matrigel (BD Biosciences, Palo Alto, CA) into the right flank of the
animal. Animals were checked twice weekly for the development
of palpable tumors at the site of injection.
Tumor therapy studies
In the first 225Ac-E4G10 monotherapy study, mice were engrafted
with 1 million LNCaP cells. The test group received 50 nCi of
225Ac labeled E4G10. Controls included vehicle (received 1%
human serum albumin), unlabeled E4G10 (received 7 mg E4G10),
225Ac labeled isotype control (received 50 nCi [0.6 mg] of 225Ac
labeled irrelevant rat IgG2a). Treatments were administered at 3,
5, 7 and 10 days post-implantation of xenografts. In the second
225Ac-E4G10 monotherapy study, mice were injected with 5
million LNCaP cells and treated on days 3, 5, 7 and 10 days post
xenograft implantation with either vehicle (received 1% human
serum albumin), 50 nCi of 225Ac labeled irrelevant isotype control
IgG mixed with 7 mg of unlabeled specific E4G10 (dual control) or
50 nCi of 225Ac labeled E4G10. For the combination therapy
study, 225Ac labeled E4G10 or isotype control antibody (50 nCi)
was administered at 16, 18, 21 and 23 days post-implantation with
5 million LNCaP cells. Paclitaxel (20 mg/kg i.p.) was administered
to the specified groups on days 27, 30, 34 and 37. Tumor size was
measured with calipers, and tumor volume was calculated by the
formula 0.526d1
26d2, where d1 is the smaller diameter and d2 is
the larger diameter. Animals were followed over long term for
survival advantage. Mice were bled retro-orbitally on described
days and serum prostate specific antigen (PSA) was determined
using an immunoassay kit (Alpco diagnostics, Windham, NH).
Histopathologic toxicity studies
BALB/c mice (n = 5) were injected four times with 100 nCi 225Ac-
E4G10 (twice the dose at same schedule as the tumor therapy
experiments). Animals were sacrificed 10 days after last injection
and their lungs, kidneys, heart, liver and spleen were excised, fixed
and examined by light microscopy.
Anatomic Pathology and Immunohistology
Tumors or normal organs from mice were harvested, formalin-
fixed and paraffin-embedded. Three micron sections were stained
with hematoxylin and eosin (H&E), Periodic–acid Schiff (PAS) and
Masson’s trichrome, and evaluated with an Olympus BX45 light
microscope, as described [24]. Eight micron tumor-sections were
immunostained with goat anti-CD31 (Santa Cruz Biotechnology,
Santa Cruz, CA) and mouse anti-smooth muscle actin (a-SMA;
Sigma, St. Louis, MO) as primary antibodies, biotinylated
Vascular Targeting of Tumor
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secondary antibodies and streptavidin-fluorophores as tertiary
reagents. Images were acquired on a Leica TCS SP2 AOBS
confocal laser-scanning microscope. Apoptosis was detected in
8 mm tumor-sections using the TUNEL assay (In situ cell death
detection kit; Roche). Immunoperoxidase staining was performed
for von Willebrand factor and caspase-3, using rabbit anti-von
Willebrand factor (vWF; Dako, Carpinteria, CA) and rabbit anti-
cleaved caspase-3 (Cell signaling technology, Beverly, MA), and
imaged on a Zeiss Axiovert 200M microscope. Acquired images
were evaluated using ImageJ software (http://rsb.info.nih.gov/ij).
For each of the four random fields (5716428um) of tumor sections
stained with vWF, the number of pixels of positive staining was
divided by the total number of pixels, and expressed as
a percentage. The degree of apoptosis was estimated in each
randomly selected field (11426857um) by calculating the
percentage of TUNEL positive cells out of the total number of
cells (as measured by nuclear counterstaining).
Electron Microscopy
Pieces of tumor tissue were fixed in 4% paraformaldehyde, post-
fixed in 1% Osmium tetroxide and later embedded in epon. Ultra-
thin sections (200–400 A˚) were cut on nickel grids, stained with
uranyl acetate and lead citrate and examined using a transmission
electron microscope (Hitachi H-7500, Pleasanton, CA).
Statistical analyses
Graphs were constructed using Prism (Graphpad software Inc.,
SanDiego, CA). Statistical comparisons between the experimental
groups were performed by either the Student’s t-test (two-group
comparison) or one-way ANOVA with Bonferroni’s multiple
comparison post-hoc test (three-group comparison). All statistical
comparisons were two sided and the level of statistical significance
was set at p,0.05.
RESULTS
E4G10 binds to cultured endothelial cells but not to
established vasculature
The binding specificity of the monoclonal antibody E4G10 for
endothelial cells of the neovasculature was determined in vitro and
in vivo by its binding to H5V mouse endothelioma cells, and by the
lack of specific uptake in normal tissues by imaging and
biodistribution studies (Fig. 1). In flow cytometric studies, E4G10
bound with high affinity to H5V cells (Fig 1A). X-SPECT gamma
camera images at various time-points post-injection with 111In
trace-labeled E4G10 showed no organ-specific uptake of the
radioactivity in BALB/c mice (Fig. 1B). The radioactivity
gradually cleared from the blood pool and other vascularized
organs such as heart and lungs. At later time-points, the
radioactivity remained only at the sites of IgG catabolism such
as the liver and spleen. Detailed quantitation of the biodistribution
was performed by sacrificing animals at defined time-points post-
injection with 111In-E4G10 and measuring the radioactivity in
harvested organs (Fig. 1C). Therefore, the post-mortem data
confirmed the lack of specific uptake of E4G10 in normal tissues
seen in whole body imaging study.
Figure 1. Characterization of E4G10. A, Flow cytometric analysis showing the binding of E4G10 to H5V cells, a mouse endothelioma cell line, in
comparison to binding of the positive control anti-CD31 or isotype control antibody. B, X-SPECT gamma camera images of mice (prone, nose at top)
at 24, 48 and 72 hours post-injection with 111In labeled E4G10. C, Biodistribution of 111In labeled E4G10 at specified time-points post-injection. Data
are mean 6 S.E.M. %ID/g= percentage of injected dose per gram of tissue.
doi:10.1371/journal.pone.0000267.g001
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225Ac-E4G10 inhibits the growth of prostate cancer
xenografts in mice
E4G10 did not bind the human LNCaP prostate tumor cells in
flow cytometric studies (Fig. 2A). The therapeutic efficacy of the
225Ac generator labeled E4G10 was tested in two separate
experimental trials in athymic male mice that were xenografted
with human LNCaP prostate tumors. 225Ac-E4G10 was thera-
peutically effective and significantly inhibited the growth of
tumors. None of the control treatments had any significant effects
on tumor growth (Fig. 2B & C; Fig. S2). Serum PSA, a surrogate
marker for total body prostate tumor cell burden [25], was used to
confirm the anti-tumor effects and was significantly lower (
p,0.001 vs. dual control; One way ANOVA and Bonferroni’s
post-hoc analysis) in 225Ac-E4G10 treated animals as compared to
the controls (Fig. 2D). As a consequence of the anti-tumor effect,
the median survival of 225Ac-E4G10 treated animals was longer
relative to the control groups (Fig. 2E). Therefore, even though
E4G10 did not bind to the LNCap tumors directly, treatment with
225Ac-labeled E4G10 resulted in an inhibition of tumor growth,
lower serum PSA and enhanced survival in prostate cancer
xenograft-bearing mice.
Effects of 225Ac-E4G10 treatment on tumor histology
To dissect the mechanism of growth inhibition by 225Ac-E4G10,
dual control and 225Ac-E4G10 treated animals were sacrificed at
14 and 22 days after tumor implantation (four animals per group
at each time-point), and their tumors were excised and analyzed.
The tumors in control animals were grossly hemorrhagic and on
light microscopy, displayed infiltration of tumor cell masses by
a network of markedly dilated, poorly defined, anastomosing
vascular spaces filled with extravasated RBCs (Fig. 3A; Fig. S3). In
contrast, 225Ac-E4G10 treated tumors showed groups of cohesive
tumor cells separated by bands of acellular hyalinized stroma
containing small, discrete and well-formed capillary vessels, which
were lined by endothelial cells resting on a basement membrane
(visualized with trichrome stain). Immunostaining for vWF, an
endothelial cell marker, was significantly greater in the control
tumors (p = 0.0002; Student’s t-test) relative to the 225Ac-E4G10
treated ones (Fig. 3B & C). Additionally, TUNEL assay showed
a significantly greater percentage of apoptotic cells in the 225Ac-
E4G10 treated tumors (p = 0.0125; Student’s t-test) relative to the
control tumors (Fig. 3B & D). The TUNEL assay data was
confirmed by cleaved caspase-3 immunohistochemistry (data not
shown).
225Ac-E4G10 treatment leads to a relatively
normalized tumor vasculature
To investigate whether treatment with 225Ac-E4G10, in addition
to inhibiting tumor angiogenesis, also resulted in normalization of
the residual tumor vasculature, tumor cross-sections were dual
Figure 2. 225Ac-E4G10 therapy inhibits the growth of LnCap prostate tumors. A, Flow cytometric analysis depicting the lack of E4G10 binding to
LnCap cells; J591, mouse-anti prostate specific membrane antigen is the positive control. Mouse and rat isotype controls were also evaluated. B,
Photographs of in situ (left) and excised tumor (right) in a representative dual control and 225Ac-E4G10 treated animal. C, Tumor volume in various
treatment groups at described time-points. D, Serum prostate specific antigen (PSA) levels in the three treatment groups at 22 days post-
implantation with 5 million LnCap cells. E, Kaplan Meier curve showing enhancement of survival with 225Ac-E4G10 treatment. Data in C, D are mean
6 S.E.M. Scale bar, 1 cm.
doi:10.1371/journal.pone.0000267.g002
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immunostained with CD31 (endothelial cell marker) and a-SMA
(mural cell marker). The majority of the vascular endothelial cells
in 225Ac-E4G10 treated tumor had pericyte coverage, whereas
little coverage was observed in the tumor treated with the control
agents (Fig. 4A & Movie S1). Transmission electron microscopy
revealed sinusoid like blood vessels in dual control tumor, which
were lined by tumor cells and filled with extravasated erythrocytes
(RBCs, Fig. 4 B). In contrast, most vessels in 225Ac-E4G10 treated
tumors appeared mature and were lined by a continuous layer of
endothelial cells resting on a basement membrane and surrounded
by a pericyte.
Sequential administration of 225Ac-E4G10 and
paclitaxel enhances the anti-tumor response
The structural normalization of residual tumor vasculature
following 225Ac-E4G10 treatment prompted us to ask whether
administration of a cytotoxic drug in that time-period would
enhance the overall anti-tumor response via greater accessibility of
the drug to tumor cells. Monotherapy with 225Ac-E4G10 signifi-
cantly inhibited tumor growth and enhanced animal survival
compared to controls as was observed in previous experiments
(Fig. 5A & B). However, subsequent bi-weekly administration of
paclitaxel for two weeks, starting four days after the last 225Ac-
E4G10 injection resulted in a significant enhancement of the
anti-tumor response compared to 225Ac-E4G10 monotherapy.
Median survival for the specific combination treatment group
was 182 days versus 113 days for the animals that received
225Ac-E4G10 alone or 84 days for animals that received 225Ac
labeled isotype antibody and paclitaxel. Three animals each from
the 225Ac-E4G10 and 225Ac-isotype control (IgG2a) group were
sacrificed before commencement of paclitaxel therapy for
histopathologic analyses of the tumor vasculature. As observed
earlier (Fig. 3A), the tumor vasculature in 225Ac-E4G10 treated
animals, though less extensive than that seen in 225Ac-isotype
treated animals, displayed a relatively greater structural maturity
(data not shown).
225Ac-E4G10 is not toxic at therapeutically active
doses
The animals that received 225Ac labeled E4G10 or the isotype
control antibody initially lost body weight (,10%), which was
recovered within 2 weeks. Histopathologic toxicity was studied in
animals (n = 5) that received twice the dose of 225Ac-E4G10 at
same schedule as in the therapy experiments. No evidence of
vascular leakage or hemorrhage was observed in any of the
examined normal organs (Fig. 5C). Additionally, the organs did
not reveal any other gross or histopathologic abnormality.
DISCUSSION
We describe a novel cancer therapy of unusual potency and
selectivity and elucidate its mechanism. Collectively, our data
demonstrate the safety and effectiveness of specific delivery of
short-ranged alpha particles to endothelial cells in inhibiting
endothelial cell proliferation and tumor new vessel formation,
Figure 3. Effect of 225Ac-E4G10 therapy on tumor histology, vascularity and apoptosis. A, Light microscopy depicting numerous RBC-filled vascular
spaces (arrows) in dual control tumor and fewer, but relatively normal-looking vessels (arrowheads) in the 225Ac-E4G10 treated tumor. B, Top:
Immunohistochemical staining of tumor-sections for vWF, an endothelial cell marker (top). TUNEL staining of tumor sections to detect apoptosis
(bottom). Quantification of vWF staining (C) and apoptosis (D) in 4 randomly selected fields. Data are mean 6 S.E.M.
doi:10.1371/journal.pone.0000267.g003
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resulting in suppression of tumor growth. Additionally, the
treatment resulted in a relatively mature remaining tumor
vasculature and an enhanced overall anti-tumor response when
combined with subsequently administered chemotherapy.
Most anti-angiogenic therapies that are being developed or have
been approved target cytokines, growth factors or their receptors.
However, tumors may circumvent therapies aimed at a single
signaling pathway via up-regulation of alternate pathways and
therefore, targeting of multiple angiogenic pathways has been
suggested [26,27,28]. Selective killing of endothelial cells in the
tumor neovasculature or their progenitors with a cytotoxic agent is
an attractive alternative approach to overcome the acquired
resistance. We exploited the exclusive binding specificity of the
antibody E4G10 for the endothelial cells of the neovasculature as
well as VE Cadherin positive EPCs in the bone marrow and blood
via its proposed targeting of an epitope exposed only on the
monomeric, unengaged form of VE cadherin, which gets masked
on the formation of adherens junctions between adjacent
endothelial cells (Fig. S1). Therefore, based on the proposed
mechanism, the antibody should not target established vascula-
ture. Our in vivo imaging and post-mortem biodistribution data
confirm the proposed selectivity of the antibody for neovasculature
and EPCs. The uptake of radioactivity seen in the lungs and the
heart was due to the presence of radiolabeled antibody in the
blood pool in these organs and it declined in proportion to the
blood clearance of radiolabeled antibody. As a consequence of
selective targeting of a minor subpopulation of cells, in conjunction
with the short range of the alpha particles, no discernible toxicity
was seen in therapy studies with 225Ac-E4G10. Additionally,
administration of supra-therapeutic doses of 225Ac-E4G10 in mice
did not result in any histopathologic abnormality, vascular leak or
hemorrhage in normal organs as has been seen with other VE-
cadherin-binding antibodies that disrupt adherens junctions in
established vessels [17]. This result further validated the
pharmacokinetic data that E4G10 did not specifically accumulate
in normal tissues with established blood vessels as the target VE-
cadherin epitope for EG410 is masked in those vessels.
225Ac was considered as a suitable cytotoxic agent for coupling
to E4G10 because of its four alpha particle emissions per decay of
a 225Ac atom, which contributes to the enhanced the potency of
225Ac labeled constructs. 225Ac labeled antibodies have been
shown to be safe and potent anti-tumor agents in mouse models of
solid prostatic carcinoma, disseminated lymphoma, intra-perito-
neal ovarian cancer and in a rat model of meningeal neuroblas-
toma [20,21,23,29]. The high energy (5–8 MeV) and short path-
length (50–80 mm) makes alpha particles the most appropriate
form of radiation for targeting of individual endothelial cells [21].
Even though EG410 did not bind to the LNCaP cells, treatment
with 225Ac labeled E4G10 resulted in an inhibition of tumor
growth, lower serum PSA and enhanced survival in prostate
cancer xenograft-bearing mice, accompanied by a decrease in
tumor blood vessel density (as evidenced by vWF immunostain-
ing). Although 225Ac-E4G10 inhibited tumor growth, it did not
eradicate tumors when used as a single agent. The result is
consistent with the vascular-targeting mechanism of action of
225Ac-E4G10. Since the tumor cells are not targeted, the residual
tumor cells (as seen in Fig. 3a) can initiate a second phase of
angiogenesis which results in a resurgence in tumor growth.
Figure 4. 225Ac-E4G10 treatment results in a relatively normal remaining tumor vasculature. A, Greater coverage of tumor blood vessels (CD31
positive) by pericytes (a-SMA-positive cells) in 225Ac-E4G10 treated tumor relative to dual control. B, Transmission electron micrographs of blood
vessels in dual control and 225Ac-E4G10 treated tumor. The dual control tumor contains extravasated RBC-filled vascular spaces that are not lined with
endothelial cells, whereas blood vessels in 225Ac-E4G10 treated tumor display a continuous endothelial lining (arrow) resting on a basement
membrane (BM) that is shared with the surrounding pericyte. Scale bar, 50 mm
doi:10.1371/journal.pone.0000267.g004
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Specific depletion of VE-cadherin positive endothelial cells of the
tumor neovasculature with 225Ac labeled E4G10 is one explana-
tion for the observed decrease in tumor blood vessel density.
Recently, it has been shown that hypoxic stress can enhance the
release of endothelial progenitors from the bone marrow and their
recruitment and incorporation into tumor vasculature [30].
Selective alpha particle-mediated killing of the VE-cadherin
positive late endothelial progenitors in the bone marrow or
circulating endothelial progenitor cells in the blood stream (which
are readily accessible to the radiolabeled antibody) is another
mechanism via which 225Ac-E4G10 may have inhibited tumor
angiogenesis. Our related manuscript (Nolan et al, submitted)
describes, in a Lewis lung cancer model, the mobilization of VE
cadherin positive EPCs from the bone-marrow into the peripheral
circulation and their incorporation into tumor neovessels.
Treatment with 225Ac-E4G10 resulted in a significant decrease
in the bone-marrow derived endothelial cell progenitors in the
tumor and a lower tumor vessel density. Another plausible
contribution to the pronounced inhibition of tumor growth,
besides direct cytotoxicity to tumor neovascular endothelial cells or
their progenitors, can be from the local release of a-particle
emitting daughters of 225Ac (francium-221, astatine-217 and
bismuth-213[19] in the tumor microenvironment as a result of
225Ac decay following binding of 225Ac-E4G10 to VE cadherin
positive endothelial cells in nascent tumor vasculature.
Histopathologic examination of control tumors revealed
a network of dilated, anastomosing vascular spaces that formed
between tumor cell nests and were filled with extravasated RBCs.
Although these tumors displayed significantly greater staining for
vWF as compared to 225Ac-E4G10 treated ones, most of these
vascular channels were not lined by endothelial cells and therefore,
did not stain for vWF. Moreover, most vWF positive structures in
the control tumors did not possess a lumen and may represent
endothelial sprouts growing into the tumor [31]. These findings
are consistent with previous data on this tumor model [32,33]. A
transient breach in vessel wall integrity secondary to growth factor-
driven active endothelial cell proliferation and sprouting may have
resulted in the extravasation of RBCs and the resultant intra-
tumoral hemorrhage [31].
Blood vessels in tumors are abnormal in structure (dilated and
torturous with abnormal basement membrane and inadequate
pericyte coverage) and function (hyperpermeable; [11]. Tumor
Figure 5. A combination of 225Ac-E4G10 with paclitaxel enhances the anti-tumor response. A, Tumor volume in the four treatment groups over
time. Data are mean 6 S.E.M. B, Kaplan Meier survival curve of treated animals showing significant enhancement of animal survival when 225Ac-
E4G10 therapy is followed by a course of paclitaxel. C, Absence of histopathologic damage in normal organs, assessed 10 days after cessation of
225Ac-E4G10 treatment.
doi:10.1371/journal.pone.0000267.g005
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vessel leakiness correlates closely with histologic tumor grade [34].
A functionally compromised vasculature also precludes efficient
delivery of oxygen and chemotherapeutics to the tumors.
Furthermore, tumor hypoxia makes cancer cells resistant to
radiation damage [35]. Previous studies have shown that in-
hibition of VEGF signaling can ‘‘normalize’’ the blood vessels and
therefore, overcome these pharmacokinetic barriers to drug and
oxygen delivery [15,35]. An interesting finding in our study was
that treatment with 225Ac-E4G10, in addition to reducing tumor
blood vessel density, also resulted in a structurally mature residual
tumor vasculature wherein a greater proportion of vascular
endothelial cells had pericyte coverage as compared to control
tumors. This could be attributed to pruning of immature tumor
vessels via killing of excess endothelial cells or EPCs by treatment
with 225Ac-E4G10. Therefore, inhibition of abnormal endothelial
cell proliferation and the resultant vessel leak may possibly be the
reason for the relatively normal residual tumor vasculature seen in
our studies. The role of pericyte coverage in inhibiting metastasis
in a murine pancreatic cancer model has been shown recently
[36]. An inverse correlation between pericyte coverage and
hematogenous spread has also been observed in colorectal cancer
patients [37]. The effects of 225Ac-E4G10 treatment on tumor
metastasis and invasiveness are currently being investigated.
Combination therapy wherein 225Ac-E4G10 treatment was
followed by a course of paclitaxel resulted in an enhancement of
the overall anti-tumor response. One plausible explanation for that
effect is that the structural normalization of tumor vasculature by
225Ac-E4G10 treatment resulted in increased efficiency of the
vessels in delivering the chemotherapeutic to the tumor cells,
thereby leading to synergy. Alternatively, the two treatments may
also have an additive effect by killing two distinct populations of
cells (endothelial and tumor cells). Paclitaxel has also been shown
to possess anti-angiogenic properties [38] but recent data by
Kerbel et al suggests that the cremophor-based paclitaxel
formulation (which was used in our experiments) does not have
a significant impact on the tumor vasculature or viability of
circulating endothelial progenitors [39]. Nonetheless, killing of
tumor cells by a cytotoxic agent can possibly decompress blood
vessels in a tumor and therefore, increase blood flow. The exact
mechanism of the enhanced overall response is currently being
investigated.
Our results allude to the development of an integrative
approach to cancer therapy wherein 225Ac-E4G10 therapy is
precisely timed with chemotherapy or radiation to maximize the
delivery of the chemotherapeutic and to improve radiation
sensitivity of tumors. Delivering the two treatment modalities in
a carefully planned temporal fashion can potentially result in
a synergistic effect on tumor-cell killing. Importantly, our data
suggest that targeting the tumor cells or their microenvironment
may not be necessary to slow cancer growth if the angiogenic
progenitors, a relatively small but possibly sensitive cell population,
can be selectively depleted.
SUPPORTING INFORMATION
Figure S1 Schematic depicting the selectivity of E4G10 for the
unengaged form of VE-cadherin molecule and the effect of 225Ac-
E4G10 therapy on tumor vasculature.
Found at: doi:10.1371/journal.pone.0000267.s001 (2.79 MB TIF)
Figure S2 225Ac-E4G10 therapy inhibits the growth of LnCap
prostate tumors. A, Tumor volume in various treatment groups
(n = 5) at 30 days post-implantation with 1 million LnCap cells in
Matrigel. B, Serum prostate specific antigen (PSA) levels in the
different treatment groups at 42 days post-implantation C, Kaplan
Meier survival curve showing enhancement of survival with
225Ac-E4G10 treatment. Data in A, B are mean 6 s.e.m.
Asterisk, P,0.05 vs. [Ac-225] IgG2a isotype control (One way
ANOVA and Bonferroni’s post-hoc analysis).
Found at: doi:10.1371/journal.pone.0000267.s002 (2.30 MB TIF)
Figure S3 Effect of 225Ac-E4G10 therapy on tumor histology at
14 days post-tumor implantation. Light microscopy revealing
numerous dilated, anastomosing, RBC-filled vascular spaces in
dual control tumor and fewer, but relatively normal-looking vessels
in 225Ac-E4G10 treated tumor.
Found at: doi:10.1371/journal.pone.0000267.s003 (5.03 MB TIF)
Movie S1 Treatment with 225Ac-E4G10 leads to relatively
mature remaining tumour vasculature. Three dimensional re-
construction stack of serial Z-plane slices (z-stack) through the
225Ac-E4G10 treated tumor section, immunostained for endo-
thelial cells (CD31, green) and pericytes (SMA, violet). The
endothelial cells display significant pericyte coverage. Image
dimensions, 1406140 mm; 72 sections in z-dimension; total
thickness, 12 mm.
Found at: doi:10.1371/journal.pone.0000267.s004 (6.94 MB AVI)
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